Check Before You Invest : Genomic Valley Biotech Ltd

Q: Which industry/sub-sector does Genomic Valley Biotech Ltd belong to?

Genomic Valley Biotech Ltd belongs to the Agriculture & Allied activities sector, operating specifically within the Agriculture segment.

Q: Is Genomic Valley Biotech Ltd a good quality company?

Genomic Valley Biotech Ltd is a quality company, based on a multi-year financial track record. This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q: Is Genomic Valley Biotech Ltd undervalued or overvalued?

Genomic Valley Biotech Ltd appears Somewhat Undervalued, as its key valuation ratios are lower than their past averages. Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more. Valuation Ratios. Price to Earnings, Current: -, Historic Median: 18.66. Price to Book, Current: 1.83, Historic Median: 2.61. Price to Sales, Current: 14.6, Historic Median: 15.45. EV to EBITDA, Current: 160.15, Historic Median: 10.36

Q: Is Genomic Valley Biotech Ltd a good buy now?

Genomic Valley Biotech Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Q: Revenue growth of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd revenue growth is 394.1% for FY-2025, which is above its 5-year CAGR of -0.24%, indicating faster growth.

Q: Gross Profit margin of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Gross profit margin which is the profit after deduction of direct costs, is 52.6% for FY-2025, which is above its 5-year median of 9.8%, indicating increasing margins.

Q: Operating Profit Margin of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 52.1% for FY-2025, which is above its 5-year median of 9.32% indicating increasing margins.

Q: Net Profit Margin of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Net Profit Margin is 42.19% for FY-2025, is above its 5-year median of 9.2%, indicating increasing margins. Profitability Metrics. Gross Profit Margin (%), Current: 52.6, Historic Median: 9.8. Operating Profit Margin (%), Current: 52.1, Historic Median: 9.32. Net Profit Margin (%), Current: 42.19, Historic Median: 9.2

Q: Return on Asset of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Return on Asset is 8.2%, which is above its 5-year historical median of 0.35%, indicating improved asset utilization efficiency.

Q: Return on capital employed (ROCE) of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Return on capital employed is 11.87% for FY-2025, which is above its 5-year historical median of 0.93%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Check Before You Invest : Genomic Valley Biotech Ltd

Snapshot

Q.1 Which industry/sub-sector does Genomic Valley Biotech Ltd belong to?

Genomic Valley Biotech Ltd belongs to the Agriculture & Allied activities sector, operating specifically within the Agriculture segment.

Q.2 Is Genomic Valley Biotech Ltd a good quality company?

Genomic Valley Biotech Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Genomic Valley Biotech Ltd undervalued or overvalued?

Genomic Valley Biotech Ltd appears Somewhat Undervalued, as its key valuation ratios are lower than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios	Current	5-year Historic Median
Price to Earnings	-	18.66
Price to Book	1.83	2.61
Price to Sales	14.6	15.45
EV to EBITDA	160.15	10.36

Q.4 Is Genomic Valley Biotech Ltd a good buy now?

Genomic Valley Biotech Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd revenue growth is 394.1% for FY-2025, which is above its 5-year CAGR of -0.24%, indicating faster growth.

Q.2 Gross Profit margin of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Gross profit margin which is the profit after deduction of direct costs, is 52.6% for FY-2025, which is above its 5-year median of 9.8%, indicating increasing margins.

Q.3 Operating Profit Margin of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 52.1% for FY-2025, which is above its 5-year median of 9.32% indicating increasing margins.

Q.4 Net Profit Margin of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Net Profit Margin is 42.19% for FY-2025, is above its 5-year median of 9.2%, indicating increasing margins.

	Current Level	5-year Historic Median
Gross Profit Margin (%)	52.6	9.8
Operating Profit Margin (%)	52.1	9.32
Net Profit Margin (%)	42.19	9.2

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Return on Asset is 8.2%, which is above its 5-year historical median of 0.35%, indicating improved asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Return on capital employed is 11.87% for FY-2025, which is above its 5-year historical median of 0.93%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Q.7 Return on Equity (ROE) of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Return on equity is 9.57% for FY-2025, which is above its 5-year historical median of 0.43%, indicating the business is making better use of its shareholders capital.

Q.8 Cash conversion cycle of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Cash conversion cycle is 906 days, above its 5-year historical median of 193 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover (x)	0.19	0.04
ROE (%)	9.57	0.43
ROCE (%)	11.87	0.93
Cash Conversion Cycle	906 days	193 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Debt-to-Equity ratio is 0.00, which is lower the industry average of 0.13, indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd Debt to cash flow from operations is 0, which is at a healthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Genomic Valley Biotech Ltd?

Q.1 Promoter shareholding and pledge status of Genomic Valley Biotech Ltd?

Promoters hold 46.06% of the Genomic Valley Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Genomic Valley Biotech Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Genomic Valley Biotech Ltd vs industry peers?

Genomic Valley Biotech Ltd revenue CAGR is -0.24%, compared to the industry median CAGR of 0.00%, indicating slower growth and losing its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth (%)	394.1	0
Gross Profit Growth (%)	2,100	15.2
Operating Profit Growth (%)	2,100	21.2
Net Profit Growth (%)	1,700	8.5

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover (x)	0.19	0.53
ROE (%)	9.57	7.6
ROCE (%)	11.87	8.57
Cash Conversion Cycle (days)	906.48	73

Valuation & price assessment

Q.1 Stock return of Genomic Valley Biotech Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 0.02% based on the current price.

	9Y	5Y	3Y	1Y
Share Price CAGR	-	0%	2.8%	-60.1%

Q.2 Valuation ratios of Genomic Valley Biotech Ltd vs historical?

The current P/E ratio of 0 is lower than its historical median of 18.66, indicating that the stock is trading below its historical average valuation.

Q.3 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	-	18.66	20.70
Price to Book	1.83	2.61	1.93
Price to Sales	14.6	15.45	1.89
EV to EBITDA	160.15	10.36	13.08

Check more companies

1. Kaveri Seed

2. Venkys India

3. AVT Natural Prod

4. Bombay Super Hybrid

5. Regaal Resources

6. Freshara Agro Export

7. Mangalam Global Ent

8. Kotyark Industries

9. Nath Bio-Genes

10. Sheetal Universal

Check trending companies

1. IFCI Ltd.

2. Aditya Birla Lifestyle Brands Ltd.

3. Aditya Birla Capital Ltd.

4. Tata Steel Ltd.

5. Nippon Life India Asset Management Ltd.

Check Before You Invest : Genomic Valley Biotech Ltd

Snapshot

Performance Analysis

Ownership & governance

Peer comparison (industry-wise, mcap)

Profit Metrics

Operating Efficiency

Valuation & price assessment

Check more companies

Check trending companies

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.